India's first dengue vaccine Qdenga: Safety caveat for seronegative children
India has approved Qdenga, its first dengue vaccine, designed to protect against all four serotypes of the virus. However, clinical trial data from manufacturer Takeda raises a crucial safety concern, particularly for seronegative children (those not previously infected). The vaccine could potentially enhance dengue in these children, specifically against DENV-3, and its efficacy against DENV-4 remains unknown. Experts recommend screening for prior dengue exposure before vaccination for seronegative recipients to mitigate the risk of Antibody-Dependent Enhancement (ADE).
Key Points
- India has approved Qdenga, its first dengue vaccine, targeting all four serotypes.
- A significant safety caveat exists for seronegative children, who may experience enhanced dengue (ADE).
- Qdenga's efficacy against DENV-3 is problematic for seronegative individuals, and DENV-4 efficacy is unknown.
- Screening for prior dengue exposure is recommended for seronegative recipients to avoid potential risks.
Exam Facts
- Qdenga is manufactured by the Japanese pharmaceutical company Takeda.
- The vaccine is designed to protect against DENV-1 to DENV-4 serotypes.
- Clinical trial data was published in 2019, 2020, and 2024.
- The phenomenon of enhanced infection is called Antibody-Dependent Enhancement (ADE).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.